These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 35862449)

  • 1. Polygenic Risk Score and Statin Relative Risk Reduction for Primary Prevention of Myocardial Infarction in a Real-World Population.
    Oni-Orisan A; Haldar T; Cayabyab MAS; Ranatunga DK; Hoffmann TJ; Iribarren C; Krauss RM; Risch N
    Clin Pharmacol Ther; 2022 Nov; 112(5):1070-1078. PubMed ID: 35862449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive Utility of a Coronary Artery Disease Polygenic Risk Score in Primary Prevention.
    Marston NA; Pirruccello JP; Melloni GEM; Koyama S; Kamanu FK; Weng LC; Roselli C; Kamatani Y; Komuro I; Aragam KG; Butterworth AS; Ito K; Lubitz SA; Ellinor PT; Sabatine MS; Ruff CT
    JAMA Cardiol; 2023 Feb; 8(2):130-137. PubMed ID: 36576811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polygenic Risk Score Identifies Subgroup With Higher Burden of Atherosclerosis and Greater Relative Benefit From Statin Therapy in the Primary Prevention Setting.
    Natarajan P; Young R; Stitziel NO; Padmanabhan S; Baber U; Mehran R; Sartori S; Fuster V; Reilly DF; Butterworth A; Rader DJ; Ford I; Sattar N; Kathiresan S
    Circulation; 2017 May; 135(22):2091-2101. PubMed ID: 28223407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
    Rosenblit PD
    Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetically predicted on-statin LDL response is associated with higher intracerebral haemorrhage risk.
    Mayerhofer E; Malik R; Parodi L; Burgess S; Harloff A; Dichgans M; Rosand J; Anderson CD; Georgakis MK
    Brain; 2022 Aug; 145(8):2677-2686. PubMed ID: 35598204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statins and atherosclerotic cardiovascular outcomes in patients on incident dialysis and with atherosclerotic heart disease.
    Shavadia JS; Wilson J; Edmonston D; Platt A; Ephraim P; Hall R; Goldstein BA; Boulware LE; Peterson E; Pendergast J; Scialla JJ
    Am Heart J; 2021 Jan; 231():36-44. PubMed ID: 33096103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of Trends in Statin Therapy for Secondary Prevention of Atherosclerotic Cardiovascular Disease in US Adults From 2007 to 2016.
    Yao X; Shah ND; Gersh BJ; Lopez-Jimenez F; Noseworthy PA
    JAMA Netw Open; 2020 Nov; 3(11):e2025505. PubMed ID: 33216139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coronary Artery Calcium Versus Pooled Cohort Equations Score for Primary Prevention Guidance: Randomized Feasibility Trial.
    Muhlestein JB; Knowlton KU; Le VT; Lappe DL; May HT; Min DB; Johnson KM; Cripps ST; Schwab LH; Braun SB; Bair TL; Anderson JL
    JACC Cardiovasc Imaging; 2022 May; 15(5):843-855. PubMed ID: 34922872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-density lipoprotein cholesterol response after statin initiation among persons living with human immunodeficiency virus.
    Burkholder GA; Muntner P; Zhao H; Mugavero MJ; Overton ET; Kilgore M; Drozd DR; Crane HM; Moore RD; Mathews WC; Geng E; Boswell S; Floris-Moore M; Rosenson RS
    J Clin Lipidol; 2018; 12(4):988-998.e5. PubMed ID: 29853312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial.
    Giugliano RP; Keech A; Murphy SA; Huber K; Tokgozoglu SL; Lewis BS; Ferreira J; Pineda AL; Somaratne R; Sever PS; Pedersen TR; Sabatine MS
    JAMA Cardiol; 2017 Dec; 2(12):1385-1391. PubMed ID: 29117276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of Low-density Lipoprotein Cholesterol Level-Guided Statin Treatment in Patients With Borderline Cardiovascular Risk.
    Kohli-Lynch CN; Bellows BK; Thanassoulis G; Zhang Y; Pletcher MJ; Vittinghoff E; Pencina MJ; Kazi D; Sniderman AD; Moran AE
    JAMA Cardiol; 2019 Oct; 4(10):969-977. PubMed ID: 31461121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey.
    Kones R
    Drug Des Devel Ther; 2011; 5():325-80. PubMed ID: 21792295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association Between Achieved Low-Density Lipoprotein Levels and Major Adverse Cardiac Events in Patients With Stable Ischemic Heart Disease Taking Statin Treatment.
    Leibowitz M; Karpati T; Cohen-Stavi CJ; Feldman BS; Hoshen M; Bitterman H; Suissa S; Balicer RD
    JAMA Intern Med; 2016 Aug; 176(8):1105-13. PubMed ID: 27322095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of Nontraditional Risk Markers in Individuals Ineligible for Statin Therapy According to the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines.
    Yeboah J; Polonsky TS; Young R; McClelland RL; Delaney JC; Dawood F; Blaha MJ; Miedema MD; Sibley CT; Carr JJ; Burke GL; Goff DC; Psaty BM; Greenland P; Herrington DM
    Circulation; 2015 Sep; 132(10):916-22. PubMed ID: 26224808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of Incident Atherosclerotic Cardiovascular DiseaseEvents by Achieved Atherogenic Lipid Levels Among62,428 Statin-Treated Individuals With Diabetes Mellitus.
    Rana JS; Liu JY; Moffet HH; Boklage SH; Khan I; Karter AJ
    Am J Cardiol; 2018 Sep; 122(5):762-767. PubMed ID: 30057224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial.
    Vallejo-Vaz AJ; Fayyad R; Boekholdt SM; Hovingh GK; Kastelein JJ; Melamed S; Barter P; Waters DD; Ray KK
    Circulation; 2018 Aug; 138(8):770-781. PubMed ID: 29618599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: comparison with the National Institute for Health and Care Excellence (NICE) 2014 lipid modification guidelines.
    Steen DL; Khan I; Ansell D; Sanchez RJ; Ray KK
    BMJ Open; 2017 Feb; 7(2):e013255. PubMed ID: 28213597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of statin therapy in adults with coronary heart disease.
    Wilt TJ; Bloomfield HE; MacDonald R; Nelson D; Rutks I; Ho M; Larsen G; McCall A; Pineros S; Sales A
    Arch Intern Med; 2004 Jul; 164(13):1427-36. PubMed ID: 15249352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of Statins as Primary Prevention in People With Gout: A Population-Based Cohort Study.
    Garcia-Gil M; Comas-Cufí M; Ramos R; Martí R; Alves-Cabratosa L; Parramon D; Prieto-Alhambra D; Baena-Díez JM; Salvador-González B; Elosua R; Dégano IR; Marrugat J; Grau M
    J Cardiovasc Pharmacol Ther; 2019 Nov; 24(6):542-550. PubMed ID: 31248268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LPA Variants Are Associated With Residual Cardiovascular Risk in Patients Receiving Statins.
    Wei WQ; Li X; Feng Q; Kubo M; Kullo IJ; Peissig PL; Karlson EW; Jarvik GP; Lee MTM; Shang N; Larson EA; Edwards T; Shaffer CM; Mosley JD; Maeda S; Horikoshi M; Ritchie M; Williams MS; Larson EB; Crosslin DR; Bland HT; Pacheco JA; Rasmussen-Torvik LJ; Cronkite D; Hripcsak G; Cox NJ; Wilke RA; Stein CM; Rotter JI; Momozawa Y; Roden DM; Krauss RM; Denny JC
    Circulation; 2018 Oct; 138(17):1839-1849. PubMed ID: 29703846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.